$VRTX · Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated filed a Form 4 with the SEC reporting a change in beneficial ownership by Nancy Thornberry, a director of the company. The filing discloses that on November 16, 2026, Ms. Thornberry sold 1,000 shares of Vertex common stock at a price of $547.86 per share. Following the transaction, she directly held 1,109 shares of common stock.
The sale was made pursuant to a company-approved trading plan under Rule 10b5-1, which Ms. Thornberry entered into on August 15, 2026. The filing notes that the transaction was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). No other securities or derivative transactions were reported in this filing.